肿瘤学随着GIT癌症试验报名结束，生物技术公司收益

2026-02-25 03:45

Oncolytics Biotech (ONCY) traded higher on Tuesday after the Canadian biotech company announced that it has decided to end enrollment in its Phase 1/2 GOBLET study for a drug regimen comprising pelareorep, its experimental therapy for gastrointestinal cancers.
Concurrently, the company disclosed plans to focus on registrational and registration-enabling studies in squamous cell anal cancer (SCAC), the most common type of anal cancer, and metastatic colorectal cancer (CRC), a rare cancer.
In this regard, Oncolytics (ONCY) stated that it will meet with the FDA in mid-April to seek regulatory feedback on a single-arm registrational trial, which it expects will be sufficient to obtain U.S. approval for pelareorep in SCAC.
The company explained that it decided to end additional enrollments for Germany-based GOBLET Cohort 5 in metastatic pancreatic ductal adenocarcinoma as part of its cost-saving measures and renewed focus on SCAC and CRC.

More on Oncolytics Biotech